Skip to content

Safety and Effectiveness of Sonu for Pediatric Nasal Congestion

Safety and Effectiveness of Sonu Acoustic Resonance Therapy for the Treatment of Pediatric Patients With Moderate to Severe Nasal Congestion.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06773013
Enrollment
31
Registered
2025-01-14
Start date
2025-01-09
Completion date
2025-03-30
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal Congestion and Inflammations

Brief summary

To demonstrate the safety and effectiveness of Sonu for the treatment of pediatric patients with moderate to severe nasal congestion.

Interventions

DEVICEAcoustic Resonance (Sound) Therapy

Sonu consists of an acoustic Vibrational Headband worn circumferentially at the level of the forehead; and a Smartphone App, paired to the Headband. The App determines acoustic resonant frequencies of the subject's nasal cavity (using the facial image) and delivers treatment through bone conduction transducers in the headband

Sponsors

Third Wave Therapeutics
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric subjects between the ages of 12 to 21 years * Present with symptoms of nasal congestion for 1 month or more prior to treatment * Have a 24 hour reflective nasal congestion subscore of the TNSS of 2 or more on a 0 to 3 scale at the time of screening

Exclusion criteria

* Head, nasal or sinus surgery within 3 months * Sinus infection diagnosed within the last month, or rhinitis medicamentosa * Documented history of nasal polyposis or mass * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Serious adverse events2 weeksSafety
Reduction in nasal congestion subscore2 weeksEffectiveness

Secondary

MeasureTime frameDescription
Adverse events2 weeksSafety
Total Nasal Symptom Score (TNSS)2 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026